Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer

EBioMedicine(2020)10.1016/j.ebiom.2020.102988Source: DataRank Database

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer is a research paper published in EBioMedicine (2020). On theSindex it has a DataRank of 0. It has been cited 38 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access38 citations

Download PDF

Cite:

Linked data & code

bioproject geo nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 1.95)OA: goldTopics (40)IDs (PubMed, PMC, OpenAlex)Annotations (4)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Reid Shaw ORCID,Franz X. Schaub ORCID,Isabella N. Stork,Kay E. Gurley ORCID,Caroline Bridgwater

Live enrichment

PubMed:32927276 PMC:PMC7494677 OpenAlex:https://openalex.org/W3086194977

NCI NIH HHS

Grant: U54 CA132381

NCI NIH HHS

Grant: U01 CA217883

NCI NIH HHS

Grant: R01 CA214428

NIH

Grant: CA214310

NCI NIH HHS

Grant: R33 CA214310

FWCI

1.95

Citation Percentile

0.9%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.ebiom.2020.102988

publisherhttps://doi.org/10.1016/j.ebiom.2020.102988

publisherhttps://api.elsevier.com/content/article/PII:S2352396420303649?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2352396420303649?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32927276

Fields of Study

Protein Degradation and InhibitorsPARP inhibition in cancer therapyCRISPR and Genetic Engineering

MeSH Terms

Poly(ADP-ribose) Polymerase InhibitorsBromodomain Containing ProteinsAnimalsAntineoplastic AgentsDisease Models, AnimalDrug SynergismFemaleHumansOvarian NeoplasmsProteinsGene Expression Regulation, Neoplasticsrc-Family KinasesProto-Oncogene Proteins c-bcl-2Gene Expression ProfilingXenograft Model Antitumor AssaysCell Line, TumorProtein Kinase InhibitorsTranscriptome

Keywords

DasatinibOvarian cancerPARP inhibitorPopulationMedicineCancer researchDrug resistanceOlaparibCancerBiologyOncologyInternal medicineGeneticsPoly ADP ribose polymeraseImatinibdrug combinationsPoly(adp-ribose) Polymerase InhibitorsNavitoclaxRucaparib

Sustainable Development Goals

SDG 0: Good health and well-being